Clinically, the STEPs study group recently showcased that semaglutide, a new generation of GLP-1 RAs, administered once-weekly via subcutaneous injection induced significant (>15%) weight in overweight/obese individuals with or without T2DM [20,21,22]. Here, GLP1R is linked to type 2 diabetes mellitus.